Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 27,279 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 27,279 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $1,206,004.59. Following the transaction, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. The trade was a 16.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Christopher Peetz also recently made the following trade(s):

• On Monday, February 3rd, Christopher Peetz sold 9,102 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $48.22, for a total transaction of $438,898.44.
• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total transaction of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM traded down $0.84 during mid-day trading on Tuesday, reaching $44.31. The stock had a trading volume of 350,774 shares, compared to its average volume of 513,013. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -21.94 and a beta of 1.04. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $54.23. The business has a 50 day simple moving average of $47.55 and a 200 day simple moving average of $43.60.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $99.41 million for the quarter, compared to analyst estimates of $96.64 million. On average, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at approximately $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Mirum Pharmaceuticals by 16.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 73,888 shares of the company’s stock valued at $3,055,000 after acquiring an additional 10,427 shares during the period. Woodline Partners LP lifted its position in shares of Mirum Pharmaceuticals by 22.2% during the 4th quarter. Woodline Partners LP now owns 404,404 shares of the company’s stock valued at $16,722,000 after acquiring an additional 73,399 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at approximately $897,000. Finally, Tema Etfs LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at approximately $1,735,000.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on MIRM shares. HC Wainwright increased their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Robert W. Baird increased their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research note on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $58.20.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.